Two recent independent U.S.-based academic studies analyzing around 100 million patient records each have confirmed a troubling surge in uveitis-related vision loss over the past decade – highlighting ...

A nonsteroidal eye drop formulation of dazdotuftide, TRS-01 missed its late-stage primary endpoint for controlling inflammation in uveitis, but developer Tarsier Pharma Ltd. said post-hoc analysis ...